L’Oreal to Acquire 10% Stake in Swiss Skin Care Company Galderma 

A logo is seen over the entrance of Cosmetics company L'Oreal building in Paris, August 16, 2013. (Reuters)
A logo is seen over the entrance of Cosmetics company L'Oreal building in Paris, August 16, 2013. (Reuters)
TT

L’Oreal to Acquire 10% Stake in Swiss Skin Care Company Galderma 

A logo is seen over the entrance of Cosmetics company L'Oreal building in Paris, August 16, 2013. (Reuters)
A logo is seen over the entrance of Cosmetics company L'Oreal building in Paris, August 16, 2013. (Reuters)

French cosmetics company L'Oreal is to acquire a 10% stake in Swiss skin care firm Galderma from a group of major shareholders, the two companies said on Monday.

The Swiss firm, originally set up as a joint venture between Nestle and L'Oreal, began trading on the Swiss stock exchange in late March, with its shares rising.

Galderma said L'Oreal would acquire the 10% stake for an undisclosed premium from Sunshine SwissCo AG - a consortium led by Swedish private equity firm EQT - Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd.

Galderma said it had signed a memorandum of understanding with L'Oreal to work towards a new research and development collaboration in the form of a scientific partnership focused on complementary research projects.

"It marks an ambitious step for L'Oreal, and true to our mantra of 'seize what is starting,' it allows us to explore partnering in the fast-growing aesthetics market, a key adjacency to our own pure beauty play," said Nicolas Hieronimus, Chief Executive Officer of L'Oreal.

"We fully support Galderma's management and its strategy as a leading dermatology pure player, respect its independence and are very confident in its long-term growth potential."

L'Oreal said it will not seek to be represented at Galderma's board of directors and has agreed to customary provisions for an investment of this type as part of a shareholders' agreement with Sunshine SwissCo.



Birkenstock Results Beat on Resilient Demand, Forecasts Margin Recovery

A Birkenstock shoe is displayed at Birkenstock shoe store in London, Britain, October 11, 2023. (Reuters)
A Birkenstock shoe is displayed at Birkenstock shoe store in London, Britain, October 11, 2023. (Reuters)
TT

Birkenstock Results Beat on Resilient Demand, Forecasts Margin Recovery

A Birkenstock shoe is displayed at Birkenstock shoe store in London, Britain, October 11, 2023. (Reuters)
A Birkenstock shoe is displayed at Birkenstock shoe store in London, Britain, October 11, 2023. (Reuters)

Birkenstock beat market expectations for fourth-quarter results on robust demand for its pricey footwear and forecast a recovery in margins in fiscal 2025, sending the company's shares up 7% on Wednesday.

With fresh styles becoming a priority for consumers, Birkenstock's sandals and closed-toe clogs have drawn new customers both at its own stores and at retailers.

The company bypassed steep discounting trends evident during the holiday shopping season, which Birkenstock executives said was off to a strong start globally.

"The expansion of ranges into more closed-toe silhouette has helped boost revenue, given that they offer multi-season wear," Susannah Streeter, head of money and markets at Hargreaves Lansdown, said.

Germany-based Birkenstock's average selling prices across its product range were up 8% in fiscal 2024, in part due to higher sales of clogs, the company said, adding that closed-toe styles now made up about a third of its business.

The company has invested in expanding its global store presence and increasing manufacturing capacity this year to meet demand.

While it led to a 330-basis point drop in gross margins in fiscal 2024, Birkenstock forecast a recovery in margins in fiscal 2025 as it ramps up production from new facilities.

The company reported fourth-quarter revenue of 455.8 million euros ($478.27 million), compared with the average analyst estimate of 439.2 million euros, according to data compiled by LSEG.

However, Birkenstock's forecast for fiscal 2025 revenue to increase between 15% and 17% was below estimates of 17.5% growth.

"It would appear with this incredibly healthy growth, the company is choosing to adopt a conservative approach that they expect to be able to meet and beat," BMO Capital Markets analyst Simeon Siegel said.

On an adjusted basis, Birkenstock earned 0.29 euro per share, beating estimates of 0.26 euro.